Invasive Candidiasis Clinical Trial
Official title:
A Randomized, Double-blind, Placebo Controlled Trial of Caspofungin Prophylaxis Followed by Pre-emptive Therapy for Invasive Candidiasis in High-risk Adults in the Critical Care Setting
Adults admitted to intensive care units are at risk for a variety of complications. Infections due to the fungus called candida are of particular concern. The study will test the possibility that caspofungin, a new therapy for fungal infections, can successfully reduce the rate of candida infections in subjects at risk. It will also test if caspofungin is useful in treating subjects for this disease when diagnosed using a new blood test that is performed twice weekly, permitting earlier diagnosis than current practice standards.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05763251 -
Comparison of Uncomplicated Candidemia Therapy Duration in Children
|
N/A | |
Recruiting |
NCT01438216 -
Anidulafungin Pharmacokinetics in Intensive Care Unit Patients
|
N/A | |
Terminated |
NCT01213823 -
Risk Of Severe Hepatic Injury In Patients With Invasive Candidiasis Treated With Echinocandins
|
Phase 4 | |
Completed |
NCT02491151 -
Variability of Fluconazole Concentration in Critically Ill Patients
|
N/A | |
Completed |
NCT01716988 -
Pharmacokinetics of Micafungin in Critically Ill Patients
|
N/A | |
Completed |
NCT00607763 -
Study of Mycamine® in Infants and Toddlers With Fungal Infections to Evaluate Safety and Blood Levels of the Drug
|
Phase 1 | |
Completed |
NCT00608335 -
Study of Mycamine® in Children With Fungal Infections to Evaluate Safety and Blood Levels of the Drug
|
Phase 1 | |
Completed |
NCT00786903 -
Candida Spp. in the Lower Respiratory Tract: Harmless Residents or Pathogen?
|
N/A | |
Completed |
NCT00670657 -
CRITIC - Treatment of Candidemia and Invasive Candidiasis
|
Phase 4 | |
Recruiting |
NCT04368559 -
Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation
|
Phase 3 | |
Not yet recruiting |
NCT05707832 -
A Study of ABCD for Injection in Subjects With Invasive Candidiasis and Invasive Aspergillus
|
Phase 3 | |
Recruiting |
NCT03538912 -
Early Discontinuation of Empirical Antifungal Therapy and Biomarkers
|
N/A | |
Completed |
NCT02801682 -
NOBICS - NOvel BIomarker In Invasive CandidiasiS/Candida Sepsis
|
||
Completed |
NCT02164890 -
Pharmacokinetics of Micafungin in Patients of Intensive Care Units
|
Phase 4 | |
Completed |
NCT02841501 -
Genetic Susceptibility Factors for Candidemia.
|
||
Completed |
NCT01047267 -
Pharmacokinetics of Anidulafungin on Intensive Care Unit (ICU)
|
N/A | |
Completed |
NCT00672841 -
β-D-Glucan (BDG) Surveillance With Preemptive Anidulafungin vs. Standard Care for Invasive Candidiasis in Surgical Intensive Care Unit (SICU) Patients
|
N/A | |
Completed |
NCT02734862 -
CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension
|
Phase 2 | |
Completed |
NCT01773876 -
Empirical Antifungal Treatment in ICUS
|
Phase 3 | |
Completed |
NCT00689338 -
Anidulafungin Candidemia/Invasive Candidiasis Intensive Care Study
|
Phase 3 |